Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. on August 17, 2018. The report details a material definitive agreement entered into on the same date. Note: The request metadata references "Avalo Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics
The filing reports a private placement transaction with the following financial specifics:
- Shares Sold: 1,000,000 shares of common stock.
- Purchase Price: $3.91 per share (based on the closing price on August 16, 2018).
- Gross Proceeds: $3,910,000.
- Use of Proceeds: General corporate purposes.
- Transaction Costs: No placement agent or underwriter was involved.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the issuance of 1,000,000 new shares of common stock to Armistice Capital Master Fund Ltd, a significant stockholder. This transaction was conducted as an unregistered sale of equity securities in reliance on Section 4(a)(2) of the Securities Act of 1933.
Guidance, Outlook, and Agreements
In connection with the securities purchase, the Company entered into a Registration Rights Agreement dated August 20, 2018. Key terms include:
- The Company agreed to file a registration statement for the resale of the shares sold in the private placement.
- The registration statement must be filed within 30 days of the Closing Date.
- The shares may not be offered or sold in the United States absent registration or an applicable exemption.
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard legal disclaimers.
Investor Verification Checklist
- Verify the identity of the registrant (Cerecor Inc.) versus the metadata request (Avalo Therapeutics, Inc.).
- Confirm the final closing date and net proceeds after any potential transaction costs not explicitly detailed.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Registration Rights Agreement (Exhibit 10.2) for covenants or restrictions.
- Monitor the filing of the registration statement for resale within the required 30-day window.